Lori S. Friedman, PhD

Lori S. Friedman, PhD
Senior Director, Translational Oncology
​Genentech, Inc.
South San Francisco, California

​Lori S. Friedman was trained in molecular and cell biology, earning her doctorate from the University of California, Berkeley in 1995, and completing postdoctoral research at Cambridge University, England in 1998. Lori joined the biotech company Exelixis as a research scientist, where she lead multiple oncology projects and advanced to become director of signal transduction research. In 2004, Friedman joined Genentech where she continued to focus on targeting key cancer pathways. She was attracted to Genentech because of the palpable commitment to helping patients by drawing on scientific insights. She is senior director of the Translational Oncology Department, whose research includes validation of new oncology targets, understanding mechanism of action and mechanism of resistance of compounds, in vitro and in vivo pharmacology, and using preclinical cancer models to predict which patients will benefit from new agents. In addition to her research, Friedman also leads the Genentech Women in Science and Engineering (gWISE) core team, and was honored with the Healthcare Business Women "Rising Star Award" in 2014. She has published 77 peer-reviewed manuscripts and is an inventor on 20 issued patents.